Teva has announced a massive restructuring of its business, with 14,000 jobs to be cut, and R&D operations and regional headquarters to be closed around the world.
Eli Lilly has filed its galcanezumab migraine drug with the FDA, as it looks to claim second place among a group of companies attempting to market a new class of therapies.